Document Detail


Role of iNO in the modulation of pulmonary vascular resistance.
MedLine Citation:
PMID:  19057617     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Inhaled nitric oxide (iNO) has quickly become a standard therapy for term and near-term infants with hypoxic respiratory failure and persistent pulmonary hypertension. Its effect on the lung is believed to be through the stimulation of soluble guanylyl cyclase and the increased production of cyclic guanosine 3',5'-monophosphate (cGMP). However, in addition to pulmonary vasodilation and a decrease in pulmonary vascular resistance, nitric oxide (NO) shows several additional potential beneficial effects on the lung. This article reviews NO mechanisms of action, early clinical trial of iNO and clinical aspects for the use of iNO in acute respiratory failure of the term and near-tem neonates.
Authors:
A Bin-Nun; M D Schreiber
Related Documents :
3208667 - Oligohydramnios in the second trimester of pregnancy, fetal breathing and normal lung g...
485607 - Congenital diaphragmatic hernia. new concept in management.
12712057 - Noninvasive delivery of inhaled nitric oxide therapy for late pulmonary hypertension in...
7647147 - Effect of l-arginine infusion on infants with persistent pulmonary hypertension of the ...
6883287 - Malignant histiocytosis. clinical and cytogenetic studies in a newborn and a child.
1748077 - Electromyographic study of facial expressions during pathological laughing and crying.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of perinatology : official journal of the California Perinatal Association     Volume:  28 Suppl 3     ISSN:  1476-5543     ISO Abbreviation:  J Perinatol     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-05     Completed Date:  2009-04-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8501884     Medline TA:  J Perinatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S84-92     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Section of Neonatology, The University of Chicago, Chicago, IL, USA. mschreiber@peds.bsd.uchciago.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Bronchodilator Agents / pharmacology*,  therapeutic use
Humans
Infant, Newborn
Nitric Oxide / pharmacology*,  therapeutic use
Persistent Fetal Circulation Syndrome / drug therapy
Vascular Resistance / drug effects*
Chemical
Reg. No./Substance:
0/Bronchodilator Agents; 10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanism(s) of in utero meconium passage.
Next Document:  Neurodevelopmental outcome of infants with meconium aspiration syndrome: report of a study and liter...